Human cytomegalovirus (CMV) continues to be a major threat against solid-organ transplant recipients despite significant advancements in its prophylaxis and therapy. Primary CMV infection or reactivation of latent CMV in the transplant recipients may cause CMV diseases such as flu-like viral syndrome and tissue-invasive CMV disease. In addition, CMV infection in the recipients is associated with graft rejection and higher risk of other opportunistic infections, which are collectively known as the "indirect effects" of CMV infection. Prevention strategies with antiviral drugs including ganciclovir remarkably decreased CMV disease and the "indirect effects". Two commonly employed strategies are universal prophylaxis and preemptive therapy. However, gangciclovir-resistant CMV has emerged due to mutations in CMV UL97 and UL54 genes, now requiring alternative therapeutic options to be developed. This review provides an overview of CMV infection and disease, "indirect effects" on hosts, prevention strategies, and drug resistance in solid-organ transplant recipients.
I. INTRODUCTION
Human cytomegalovirus (CMV; human herpesvirus 5) contains a linear double-stranded DNA genome of approximately 235 kbp which codes for roughly 165 genes (1) .
The icosahedral nucleocapsid is enclosed by a lipid bilayer envelope which contains viral glycoproteins. CMV generally causes subclinical infections, then establishing a lifelong latent and non-productive infection in healthy individuals.
Since CMV is a ubiquitous pathogen, approximately 70~ 100% of the world's population shows seropositivity, the evidence of infection (2) .
Solid-organ transplantation is the only therapeutic option for many end-stage organ diseases. In allogeneic solid-organ transplant recipients, immunosuppressive agents should be used to prevent graft rejection. However, non-specific suppression of cell-mediated immunity allows reactivation of latent CMV and severe CMV infection in the recipients.
Although antiviral drugs including ganciclovir have been widely used, CMV infection is still highly common amongst solid-organ transplant recipients, resulting in serious morbidity and occasional mortality (3) . This review provides a brief overview of CMV infection and disease, indirect effects on hosts, prevention strategies, and drug resistance in solid-organ transplant recipients. (Table 1) . CMV syndrome generally manifests as flu-like illness; it accompanies fever and malaise, which is commonly associated with thrombocytopenia or leukopenia induced by bone marrow suppression.
II. CMV infection and disease

CMV infection is defined as
Tissue-invasive CMV disease develops as a result of specific organ involvement. Although any organ can be affected, involvement of the gastrointestinal tract is most common, manifested by CMV gastritis, esophagitis, enteritis, and colitis (4, 5) . In addition, tissue-invasive CMV disease tends to affect the transplanted allograft, provoking graft loss (6).
In solid-organ transplantation, highly potent immunosuppressive agents should be used to prevent graft rejection.
However, this non-specific immunosuppression severely impairs the ability of the recipients to mount an effective immune response against pathogens including CMV. There- (19, 20) , and coronary artery disease in heart (23, 24) . These changes may increase the risk of opportunistic fungal, bacterial, and viral infections in CMV-infected solidorgan transplant recipients. Indeed, CMV infection or disease is found to be an independent risk factor for the development of invasive fungal diseases such as aspergillosis and candidiasis in liver (25) , heart (26), and lung (27) transplant recipients. CMV disease is also found to be an independent risk factor for opportunistic bacterial infections including nocardiosis in solid-organ transplant recipients (28) . In terms of its relation to other viral diseases, CMV-infected solid- (Table 2) , universal prophylaxis has the advantages of the protection against other herpesviral infections and a reduced incidence of the "indirect effects" such as graft rejection and other opportunistic infections. On the other hand, the major disadvantages of this strategy are drug toxicities (mainly bone marrow suppression) and late-onset CMV disease (CMV disease that occurs after completion 
V. Drug resistance
With the widespread use of universal prophylaxis and preemptive therapies, antiviral drug resistance has emerged.
Although it is still uncommon (1.8~2.2%) (39, 40) , the frequency of ganciclovir-resistant CMV in solid-organ transplant recipients has been increasing. Infection with ganciclovir-resistant CMV is associated with higher morbidity and mortality in solid-organ transplant recipients (41), especially in lung transplant recipients (42) .
Ganciclovir is a synthetic analogue of 2'-deoxyguanosine which requires three consecutive phosphorylation steps for its antiviral activity (Fig. 1) . The first phosphorylation step is 
VI. Closing remarks
With the development of antiviral drugs including ganciclovir, prevention strategies reduced CMV disease and "indirect effects" of CMV infection. However, the risk of 
